Literature DB >> 7011733

Potency of biosynthetic human insulin determined in vitro.

R D Fussgaenger, H H Ditschuneit, H Martini, H Wiebauer-De Lenardis, H Etzrodt, C Thun, H Ditschuneit, E F Pfeiffer, F Enzmann.   

Abstract

Biosynthetic human insulin (BHI) obtained from separately synthesized A- and B-chains by recombinant DNA technology with Escherichia coli fermentation was compared with human and pork insulin of high purity in vitro. Applying four biologic tests (glucose oxidation and glucose incorporation into the lipids by rat epididymal fat pads, inhibition of lipolysis, and ATP depletion of isolated fat cells) and three receptor assays (binding competition with human fat cells, IM-9 lymphocytes, and rat liver cell plasma membranes), we could not discern significant differences of the half-maximum response by these seven methods. The only variance occurred with the ATP-depletion assay. This method disclosed 10% greater maximum reversion of isoproterenol-induced ATP depletion by BHI when compared with pork insulin.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7011733     DOI: 10.2337/diacare.4.2.228

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  4 in total

1.  High affinity binding sites for proinsulin in human IM-9 lymphoblasts.

Authors:  P M Jehle; M P Lutz; R D Fussgaenger
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

2.  Evidence that human and porcine insulin differently affect the human insulin receptor: studies with monoclonal anti-insulin receptor antibodies.

Authors:  G Sesti; M A Marini; A Montemurro; P Borboni; G Di Cola; A Bertoli; R De Pirro; R Lauro
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

3.  Different binding and degradation of proinsulin, insulin and insulin-like growth factor-1 (IGF-1) in cultured renal proximal tubular cells. Implications for the prolonged serum half-life of proinsulin.

Authors:  P M Jehle; R D Fussgänger; S Stracke; R W Grunewald; F Keller
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

Review 4.  Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.